Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Verinurad Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 AME Study

NCT01910506
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study in Japanese Subjects

NCT01872832
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 and Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 and Febuxostat Drug Interaction Study

NCT01883167
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg, Febuxostat 40 mg, placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

RDEA3170 and Febuxostat Combination Study in Gout Subjects

NCT02246673
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5, RDEA3170 5 mg, Febuxostat 40 mg, Febuxostat 80 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Anaheim, California • Glendale, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

NCT03118739
View directory record Official record
Conditions
Hyperuricemia, Albuminuria, Type 2 Diabetes
Interventions
Verinurad 9 mg+Febuxostat 80 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Canyon Country, California • Chula Vista, California • Corona, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 PK/PD Study

NCT02608710
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Bioavailability Study

NCT02336594
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, RDEA3170 2.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

NCT03316131
View directory record Official record
Conditions
Asymptomatic Hyperuricemia
Interventions
Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

RDEA3170 Monotherapy in Subjects With Gout

NCT01927198
View directory record Official record
Conditions
Gout
Interventions
Placebo, RDEA3170 5 mg, RDEA3170 10 mg, RDEA3170 12.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

NCT04327024
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Granada Hills, California • Northridge, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Results available

RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02279641
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

NCT03990363
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02498652
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 2.5 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Anaheim, California • DeLand, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 6:12 PM EDT